The Endocrine Society's annual meeting, ENDO 2017, will take place April 1-4 in Orlando, FL.
Interesting T2DM: Pharmacotherapy & Obesity Outcomes
Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.
Obesity Management: ENDO 2017 Highlights
Could corticosteroid use put your patients at a greater risk of metabolic syndrome?
Endo 2017: Men’s Health
Men’s health studies presented at ENDO 2017 included a possible prostate cancer treatment and the potential of hormone therapy to prevent frailty.
Endo 2017: Improve Diabetes, Obesity Care
Three studies from ENDO 2017 focused on improving patient care through brain stimulation, an artificial pancreas system, and videoconferencing.
Can We Suppress Sugar Cravings?
Researchers sought to discover the specific physiological pathways of fibroblast growth factor 21.
Clinical Dilemmas in Diabetes
Research presented at ENDO 2017 explored options to reduce complications in patients with diabetes and microalbuminuria and patients with cystic fibrosis.
ENDO 2017: Sleep Studies
Studies presented at ENDO 2017 examined the impact of sleep disorders on gestational diabetes, bone formation, and adolescents with and without diabetes.
By clicking Accept, you agree to become a member of the UBM Medica Community.